Copyright
©The Author(s) 2018.
World J Gastroenterol. Mar 28, 2018; 24(12): 1321-1331
Published online Mar 28, 2018. doi: 10.3748/wjg.v24.i12.1321
Published online Mar 28, 2018. doi: 10.3748/wjg.v24.i12.1321
Table 7 Multivariate model for death outcome with BALAD and BALAD-2
| Variable | Hazard ratio with BALAD | Hazard ratio with BALAD-2 | ||
| HR (95%CI) | P value | HR (95%CI) | P value | |
| Diameter of the largest tumor at time of transplant (per cm) | 1.24 (1.04-1.48) | 0.016a | 1.20 (1.02-1.42) | 0.03a |
| Neutrophil-lymphocyte ratio | 1.13 (0.67-1.92) | 0.64 | 1.31 (0.78-2.19) | 0.31 |
| BALAD (per increase of 1) | 1.57 (1.27-1.96) | < 0.0001 | - | - |
| BALAD-2 (per increase of 1) | - | - | 1.37 (1.07-1.76) | 0.013a |
- Citation: Wongjarupong N, Negron-Ocasio GM, Chaiteerakij R, Addissie BD, Mohamed EA, Mara KC, Harmsen WS, Theobald JP, Peters BE, Balsanek JG, Ward MM, Giama NH, Venkatesh SK, Harnois DM, Charlton MR, Yamada H, Algeciras-Schimnich A, Snyder MR, Therneau TM, Roberts LR. Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models. World J Gastroenterol 2018; 24(12): 1321-1331
- URL: https://www.wjgnet.com/1007-9327/full/v24/i12/1321.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i12.1321